4DX4dmedical

4DMedical shares rose sharply following a new securities quotation application, likely reflecting a capital raise or option conversion bringing fresh investor attention alongside positive media coverage of its lung imaging technology and strong one-year price momentum.

4DMedical shares fell sharply amid a multi-day pattern of selling and investor risk reassessment, with no specific company announcement to explain the move, suggesting profit-taking or sentiment deterioration following recent volatility

Broad positive investor sentiment returned to ASX healthcare and health-tech stocks, with 4DMedical being highlighted as a red-hot climber without a specific company announcement.

4DMedical shares surged following a major US imaging network deal announced on May 29, 2026.

4DMedical shares dropped 10.14% on May 20, 2026, likely due to profit-taking and a broad market slide to a seven-week low driven by an oil shock and bond sell-off.

4DMedical shares rose 13.31% on May 14, 2026, likely driven by a broader investor rush into healthcare imaging stocks, as indicated by headlines about volatile trading and investor interest.

The stock moved down likely due to broad small-cap biotech sector sentiment, as evidenced by article about Cynata Therapeutics and overall small-cap biotech flows.

4DMedical received CE Mark approval for its CT:VQ imaging technology and entered a partnership with the Mayo Clinic, driving a 34% surge.

4DMedical completed a $150 million institutional placement, driving investor interest and a sharp share price rise despite the dilutive nature of the raise.

4DMedical announced UC San Diego Health as the 4th US academic user and commercial adopter of its CT:VQ pulmonary imaging technology.

4DMedical surged on a material partnership deal with the Cleveland Clinic for its CT:VQ technology, following a Canadian regulatory approval announcement.

4DMedical shares surged following Canadian regulatory approval and an expanded distribution deal with Philips.

The news article reports 4DMedical shares sinking on the prior day, but no direct cause for the specific 11.85% rise on 2025-10-03 is provided in the available articles.

No direct news on 2025-10-01 explains the move; likely driven by investor sentiment from the Stockhead article about US expansion prospects.

A Stockhead article covering the company's US market expansion generated positive attention, driving the share price up.

A similarly positioned stock (EIQ) surged 400% in recent days, likely driving sector-wide speculative interest in 4D Medical.

The stock dropped sharply on Tuesday 9 September 2025, the day after a 29% jump on favorable news, likely driven by profit-taking and speculative unwinding following the initial re-rating.

4DMedical announced extension of its imaging technology into public hospitals and a national screening network.

4DMedical received FDA 510(k) clearance for its CT:VQ imaging technology, driving a significant share price surge.

4DMedical received FDA 510(k) clearance for its CT:VQ technology, a major regulatory milestone.

4DMedical received FDA 510(k) clearance for its CT:VQ lung imaging software, a major regulatory milestone.

4DMedical received FDA 510(k) clearance for its CT:VQ lung imaging software, a major regulatory milestone.

The stock surged 27% following news that Pro Medicus invested $10 million in 4DMedical, a strategic investment announced on the prior day.